Navigation Links
Absorption Pharmaceuticals' CEO Jeff Abraham Discusses Promescent on KFI
Date:8/8/2014

LOS ANGELES, Aug. 8, 2014 /PRNewswire/ -- Jeff Abraham, CEO for Absorption Pharmaceuticals, was featured on KFI AM 640 on Wednesday, August 6, 2014, where he discussed Promescent, the first FDA-approved treatment for premature ejaculation (PE). Abraham answered callers' question regarding PE and explained how Promescent would safely and effectively improve their sex lives. 

According to statistics, more than 30 percent of men are currently struggling with premature ejaculation, much larger than the number of men who suffer from erectile dysfunction, a $10B worldwide market.  In his segment on KFI, Jeff Abraham explained how Promescent is able to provide men with superior ejaculatory control, with an extremely low side effect profile, common concerns surrounding other treatments for the disorder.

"Promescent may seem like a miracle, but it is actually just great science," says Abraham.  "Using a precise ratio of active ingredients, Promescent is able to absorb through the skin's outermost layer to the nerves below that control ejaculation.  This means men are not deprived of sensation and neither are their partners."

Listen to the full KFI interview with Absorption Pharmaceuticals CEO Jeff Abraham here:

http://www.kfiam640.com/media/podcast-john-and-ken-on-demand-JohnandKen/jane-wells-cnbc-6pm-86-25128155/

Promescent is now considered the leading PE solution in the U.S. with solid support from the medical community. Leaders in sexual medicine along with more than 1,000 urologists use Promescent as first-line therapy for premature ejaculation, replacing off-label anti-depressants and EMLA topical anesthetic.

"We're finding that an increasing portion of our business is from men who don't suffer from PE but simply want to last longer in bed," says Abraham.  "This helps men better satisfy their partners and gain sexual confidence."

Promescent is available on-line and over-the-counter at independent pharmacies across the nation.  It is safe, effective, and doctor recommended. 

For more information, please visit http://www.promescent.com/.

To set up an interview and/or media inquiries, call Tyler Barnett at 323.937.1951.


'/>"/>
SOURCE Absorption Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems announces novel test platform for interactions with the BCRP transporter
2. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
3. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
4. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
5. Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd
6. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
7. Absorption Systems Scientists Publish Peer-reviewed Paper on a Key Drug Transporter
8. Absorption Pharmaceuticals Expands Sales and Service Team to Answer Physicians Growing Demand for Promescent
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Genomic Health, Inc. (Nasdaq: GHDX ) today reported financial ... 31, 2015. --> --> Revenue ... $69.1 million in the fourth quarter of 2014, an increase of ... compared with the same period in the prior year. ... in the fourth quarter of 2015, an increase of 9 percent ...
(Date:2/10/2016)... HERTFORDSHIRE, England och ... -- Erbjudandet lämnas inte, och detta ... eller indirekt, i eller till, och inga ... uppdrag av aktieägare i, något land där ... av accept av Erbjudandet skulle strida mot ...
(Date:2/10/2016)... Mylan N.V. (NASDAQ, TASE: MYL) today announced ... December 31, 2015. --> --> ... revenues of $9.45 billion, up 28% on a constant ... of $9.43 billion. Excluding the impact of the acquisition ... generics business (the "EPD Business"), full year adjusted total ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... Life is known for throwing curves. It’s thrown quite ... gather once a year to play softball to raise money through Sun Health ... than 50 players who competed in this year’s softball tournament share a history of ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... their ongoing community involvement program, introduces a new charity campaign to raise funds ... are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) ...
(Date:2/11/2016)... ... 2016 , ... From March 4 through 6, Hidrex ... at the Walter E. Washington Convention Center in Washington, D.C. , At the ... hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company will be talking ...
(Date:2/11/2016)... Ore. (PRWEB) , ... February 11, 2016 , ... ... Medicaid coverage results in significantly higher rates of several common cancer screenings, especially ... resulting in better outcomes and survival rates. , The study,“What Does Medicaid ...
(Date:2/10/2016)... ... ... Early this week, Team Iconic at J. Walter Thompson and Nestlé KITKAT ... global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa Plan aims ... activities that focus on better farming, better lives and better cocoa. In order to ...
Breaking Medicine News(10 mins):